Flucytosine
Active ingredient · 2 therapeutic classes
- Drug class
- Other Antimycotics For Systemic Use
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 2
- FDA reports (12 mo)
- 167
Overview
Flucytosine is an active pharmaceutical ingredient in the Other Antimycotics For Systemic Use group (J02AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | January 7, 2026 |
| GB United Kingdom | MHRA | 1 | April 17, 2026 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Flucytosine Capsules USP is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus .
Candida:
Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine.
Cryptococcus:
Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY ).
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Flucytosine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 01d874f9-e073-40… · revised January 7, 2026 [PDF]
- [2]MHRA (UK) · PL463020116 · revised April 17, 2026
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.